Accurate sensitivity of quantum dots for detection of HER2 expression in breast cancer cells and tissues

Journal of Fluorescence

Volumn 23, Issue 2, 2013, Pages 293-302

  Tabatabaei Panah, Akram Sadat ^a   Jeddi Tehrani, Mahmood ^b   Ghods, Roya ^b   Akhondi, Mohammad Mehdi ^b   Mojtabavi, Nazanin ^c   Mahmoudi, Ahmad Reza ^b   Mirzadegan, Ebrahim ^b   Shojaeian, Sorour ^b   Zarnani, Amir Hassan ^b,c  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b AVICENNA RESEARCH INSTITUTE   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast cancer; Excitation wavelength; FITC; HER2; Photostability; Quantum dots; Sensitivity; Staining index; Tumor marker

Indexed keywords

BREAST CANCER; EXCITATION WAVELENGTH; FITC; HER2; PHOTO-STABILITY; SENSITIVITY; STAINING INDEX; TUMOR MARKERS;

BIOMARKERS; CELL CULTURE; CELLS; DISEASES; HISTOLOGY; MONOCLONAL ANTIBODIES; SEMICONDUCTOR QUANTUM DOTS; TUMORS;

SIGNAL DETECTION;

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; QUANTUM DOT; TUMOR MARKER;

ARTICLE; BREAST TUMOR; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; IMMUNOLOGY; LIMIT OF DETECTION; METABOLISM; PATHOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LIMIT OF DETECTION; QUANTUM DOTS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84879686632     PISSN: 10530509     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10895-012-1147-9     Document Type: Article

References (26)

1. Hall M, Kazakova I, Yao YM (1999) High sensitivity immunoassays using particulate fluorescent labels. Anal Biochem 272(2):165-170
2. Reiss P, Protiere M, Li L (2009) Core/Shell semiconductor nanocrystals. Small 5(2):154-168
3. Baker M (2010) Nanotechnology imaging probes: smaller and more stable. Nat Meth 7(12):957-962
4. Fountaine TJ, Wincovitch SM, Geho DH, Garfield SH, Pittaluga S (2006) Multispectral imaging of clinically relevant cellular targets in tonsil and lymphoid tissue using semiconductor quantum dots. Mod Pathol 19(9):1181-1191
5. Chan WC, Nie S (1998) Quantum dot bioconjugates for ultrasensitive nonisotopic detection. Science 281(5385):2016-2018
6. Resch-Genger U, Grabolle M, Cavaliere-Jaricot S, Nitschke R, Nann T (2008) Quantum dots versus organic dyes as fluorescent labels. Nat Methods 5(9):763-775
7. Walter NG, Huang CY, Manzo AJ, Sobhy MA (2008) Do-it-yourself guide: how to use the modern single-molecule toolkit. Nat Methods 5(6):475-489
8. Key TJ, Verkasalo PK, Banks E (2001) Epidemiology of breast cancer. Lancet Oncol 2(3):133-140
9. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177-182
10. Owens MA, Horten BC, Da Silva MM (2004) HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 5(1):63-69
11. Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulos G, Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R (2011) Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 12(3):236-244
12. Petak I, Schwab R, Orfi L, Kopper L, Keri G (2010) Integrating molecular diagnostics into anticancer drug discovery. Nat Rev Drug Discov 9(7):523-535
13. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707-712
14. Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME, King CR (1990) Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 8(1):103-112
15. Giepmans BN, Deerinck TJ, Smarr BL, Jones YZ, Ellisman MH (2005) Correlated light and electron microscopic imaging of multiple endogenous proteins using Quantum dots. Nat Methods 2(10):743-749
16. Snyder EL, Bailey D, Shipitsin M, Polyak K, Loda M (2009) Identification of CD44v6(+)/CD24- breast carcinoma cells in primary human tumors by quantum dot-conjugated antibodies. Lab Invest: A journal of technical methods and pathology 89(8):857-866
17. Shojaeian S, Allameh A, Zarnani AH, Chamankhah M, Ghods R, Bayat AA, Jeddi-Tehrani M (2010) Production and characterization of monoclonal antibodies against the extracellular domain of CA 125. Immunol Invest 39(2):114-131
18. Tabatabaei-Panah AS, Zarnani AH, Montaser-Kouhsari S, Chamankhah M, Ghods R, Bayat AA, Kazemi-Sefat GE, Mahmoudi SAR, Karampour MO, Shojaeian S, Jeddi-Tehrani M (2008) Production and characterizing anti-Her2 monoclonal antibodies. Yakhteh 10(2):109-120
19. Jotwani AC, Gralow JR (2009) Early detection of breast cancer: new biomarker tests on the horizon? Mol Diagn Ther 13(6):349-357
20. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sanchez Rovira P, Piccart-Gebhart MJ (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369(9555):29-36
21. Pinaud F, Clarke S, Sittner A, Dahan M (2010) Probing cellular events, one quantum dot at a time. Nat Methods 7(4):275-285
22. Leyland-Jones B, Smith BR (2011) Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls. Lancet Oncol 12(3):286-295
23. Goldman ER, Mattoussi H, Anderson GP, Medintz IL, Mauro JM (2005) Fluoroimmunoassays using antibody-conjugated quantum dots. Methods Mol Biol 303:19-34
24. Abrams B, Dubrovsky T (2007) Quantum dots in flow cytometry. Methods Mol Biol 374:185-203
25. Wu X, Liu H, Liu J, Haley KN, Treadway JA, Larson JP, Ge N, Peale F, Bruchez MP (2003) Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat Biotechnol 21(1):41-46
26. Chen C, Peng J, Xia HS, Yang GF, Wu QS, Chen LD, Zeng LB, Zhang ZL, Pang DW, Li Y (2009) Quantum dots-based immunofluorescence technology for the quantitative determination of HER2 expression in breast cancer. Biomaterials 30(15):2912-2918